Boji Pharmaceuticals-B (02142.HK) and PfizerEnter into a Non-Exclusive Licensing Agreement

According to the Zhixin Financial APP, Hengbo Pharmaceutical-B (02142.HK) announced that its wholly-owned subsidiary, Novartis Biotechnology (Suzhou) Co., Ltd. (Novartis Biotechnology), has entered into a non-exclusive licensing agreement with Pfizer to advance preclinical antibody discovery work for multiple potential indications.